Keywords: ampalex, schizophrenia, cortex, pharmaceuticals, begun, five-week, phase

Ampalex In Schizophrenia

Article | 30 May 1997

- Cortex Pharmaceuticals has begun a five-week, Phase Iplacebo-controlled safety study of its ampakine drug Ampalex (CX-516) in patients with schizophrenia. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Clozapine

Clozaril

Fazaclo

Go to drug listing